EnGene Holdings Financials
| ENGN Etf | USD 8.29 0.61 7.94% |
Short Ratio 3.74 | EPS Estimate Current Year (1.38) | EPS Estimate Current Quarter (0.37) | Return On Equity (1.23) |
EnGene |
The data published in EnGene Holdings' official financial statements typically reflect EnGene Holdings' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving EnGene Holdings' quantitative information. For example, before you start analyzing numbers published by EnGene accountants, it's essential to understand EnGene Holdings' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
EnGene Holdings Etf Summary
EnGene Holdings competes with Zenas BioPharma,, FT Vest, Zillow Group, Northern Lights, and VanEck Vectors. EnGene Holdings is entity of United States. It is traded as Etf on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| CUSIP | G3619H102 29286M105 |
| Region | Others |
| Investment Issuer | Others |
| Location | Quebec; Canada |
| Business Address | 7171 Rue Frederick |
| Etf Family | Biotechnology |
| Fund Category | Others |
| Portfolio Concentration | Others |
| Benchmark | Dow Jones Industrial |
| Website | www.engene.com |
| Phone | 514 332 4888 |
| Currency | USD - US Dollar |
EnGene Holdings Key Financial Ratios
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.22 | ||||
| Target Price | 28.86 | ||||
| Number Of Employees | 31 | ||||
| Beta | -0.76 |
EnGene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining EnGene Holdings's current stock value. Our valuation model uses many indicators to compare EnGene Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EnGene Holdings competition to find correlations between indicators driving EnGene Holdings's intrinsic value. More Info.enGene Holdings Common is one of the top ETFs in price to book as compared to similar ETFs. It also is one of the top ETFs in beta as compared to similar ETFs . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EnGene Holdings' earnings, one of the primary drivers of an investment's value.enGene Holdings Common Systematic Risk
EnGene Holdings' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. EnGene Holdings volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on enGene Holdings Common correlated with the market. If Beta is less than 0 EnGene Holdings generally moves in the opposite direction as compared to the market. If EnGene Holdings Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one enGene Holdings Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of EnGene Holdings is generally in the same direction as the market. If Beta > 1 EnGene Holdings moves generally in the same direction as, but more than the movement of the benchmark.
EnGene Holdings Thematic Clasifications
enGene Holdings Common is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
EnGene Holdings November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of EnGene Holdings help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of enGene Holdings Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of enGene Holdings Common based on widely used predictive technical indicators. In general, we focus on analyzing EnGene Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build EnGene Holdings's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.39 | |||
| Information Ratio | 0.0738 | |||
| Maximum Drawdown | 18.08 | |||
| Value At Risk | (5.95) | |||
| Potential Upside | 8.81 |
Other Information on Investing in EnGene Etf
EnGene Holdings financial ratios help investors to determine whether EnGene Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EnGene with respect to the benefits of owning EnGene Holdings security.